COMRADE Trial Results
I cannot provide results for the COMRADE trial as no evidence about this specific trial was found in the provided literature. The evidence base includes multiple guidelines and studies on metastatic castration-resistant prostate cancer (mCRPC) from NCCN, ASCO, and other major organizations, but none reference a trial named "COMRADE" (Cancer Outcomes Measurement and Research in Advanced Disease).
What the Evidence Does Show
The provided guidelines and research discuss numerous landmark trials in mCRPC, including:
Major Trials Referenced in the Evidence:
- CARD trial: Demonstrated cabazitaxel superiority over enzalutamide/abiraterone in patients previously treated with docetaxel and the alternate hormonal therapy 1
- TheraP trial: Compared Lu-177-PSMA-617 versus cabazitaxel, showing 66% PSA response rate with Lu-177-PSMA-617 versus 37% with cabazitaxel 1
- PROfound trial: Demonstrated overall survival benefit of olaparib compared to ARPI switch in patients with HRD 1
- TALAPRO-2, MAGNITUDE, PROpel trials: Evaluated PARP inhibitors combined with ARPIs 1
- CORRECT and CONCUR trials: Evaluated regorafenib (though in colorectal cancer context) 1
Trial Design Recommendations:
The Prostate Cancer Clinical Trials Working Group 3 (PCWG3) provides comprehensive guidance on trial design for CRPC studies, including outcome measures, imaging criteria, and patient stratification 1, but does not mention COMRADE.
Recommendation
If you are seeking information about a specific mCRPC trial, please verify the trial name. The COMRADE acronym may be misremembered or may refer to a trial not yet published in major guidelines, or it may be from a different disease area entirely. Consider checking ClinicalTrials.gov or contacting the study investigators directly for unpublished results.